Literature DB >> 3720830

Effects of the enantiomers of the dihydropyridine derivative 202-791 on contractility, coronary flow and ischemia-related arrhythmias in rat heart.

T Uematsu, N S Cook, R P Hof, S Vozeh, F Follath.   

Abstract

The (+)-enantiomer of the dihydropyridine 202-791 produced coronary constrictor and positive inotropic effects in Langendorff-perfused rat hearts whereas (--)-202-791 showed coronary dilator and negative inotropic effects. Both enantiomers showed the vascular effects at lower concentrations than the myocardial effects. Furthermore, the (+)-enantiomer significantly increased whilst the (--)-enantiomer reduced the number of ventricular ectopic beats occurring during coronary ligation. Arrhythmia-enhancing effects must therefore be considered when the potential therapeutic uses of calcium channel activators are discussed.

Entities:  

Mesh:

Year:  1986        PMID: 3720830     DOI: 10.1016/0014-2999(86)90723-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  The dihydropyridine derivative 202-791: interpretation of the effects of the racemate considering inverse agonistic enantiomers.

Authors:  M Damarowsky; H Lüllmann; U Ravens
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

Review 2.  Calcium channels: molecular pharmacology, structure and regulation.

Authors:  M M Hosey; M Lazdunski
Journal:  J Membr Biol       Date:  1988-09       Impact factor: 1.843

3.  Antiarrhythmic effects of a benzothiazine derivative (SD-3211) and its stereoisomer (SA3212) in anaesthetized rats and isolated perfused rat hearts compared with bepridil.

Authors:  M Fukuchi; T Uematsu; S Nagashima; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

4.  Photochemically induced thrombosis of the rat coronary artery and functional evaluation of thrombus formation by occurrence of ventricular arrhythmias. Effects of acetylsalicylic acid and a thromboxane A2 synthetase inhibitor of thrombus formation.

Authors:  M Fukuchi; T Uematsu; S Araki; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.